Biosafety Aspects of Hybridoma Technology: Nature of Risks and Approaches to Their Management
DOI:
https://doi.org/10.20535/ibb.2025.9.2.320712Keywords:
hybridoma technology, monoclonal antibodies, biosafety level, contamination risksAbstract
This study investigates the biosafety aspects of hybridoma technology, focusing on the identification and management of associated risks. Monoclonal antibodies, essential tools in immunology, biotechnology, and medicine, are primarily produced through hybridoma technology. This process involves fusing B lymphocytes from immunized animals with myeloma cells to create hybridomas, which are then cultured to produce specific antibodies. The research highlights significant contamination risks, particularly from rodent-borne viruses and other pathogens, during both in vivo and in vitro cultivation. It systematically analyzes existing strategies for identifying and mitigating these risks at various stages of monoclonal antibody production, including hybridoma identification, cell fusion, and antibody purification. The study underscores the importance of stringent biosafety protocols and optimized purification methodologies to ensure the production of high-quality, contaminant-free monoclonal antibodies. Additionally, it emphasizes the necessity of comprehensive risk assessments and the implementation of advanced contamination control systems in laboratories. The conclusions drawn from this study provide valuable insights into enhancing the safety and efficacy of monoclonal antibody production. By addressing these biosafety concerns, the research supports the widespread application of monoclonal antibodies in scientific and medical fields, ensuring their reliability and effectiveness in various diagnostic and therapeutic contexts.
References
Abba Moussa D, Vazquez M, Chable-Bessia C, Roux-Portalez V, Tamagnini E, Pedotti M, et al. Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic ap-proaches. Emerg Microbes Infect. 2024 Dec 9;14(1). DOI: 10.1080/22221751.2024.2432345
Kokojka F, Marks RS. Rapid and specific screening of monoclonal antibodies in hybridoma supernatants by an enzyme-based dipstick immunoassay. Talanta. 2025 Mar;284:127240. DOI: 10.1016/j.talanta.2024.127240
Galkin OY, Gorshunov YuV, Besarab OB, et al. Development and characterization of highly informative ELISA for the detection of IgG and IgA antibodies to Сhlamydia trachomatis. Ukr Biochem J. 2018 Jun 25;90(3):70-83. DOI: 10.15407/ubj90.03.070
Andersen RA. Preface. Algal culturing techniques. Academic Press; 2005. ch. IX-X. DOI: 10.1016/b978-012088426-1/50001-9
Khudetsky I, Antonova-Rafi Y. The influence of man and changes in nature on biological safety (overview of the problem). Phytother J. 2023 Jan;2:26-34. DOI: 10.32782/2522-9680- 2023-2-37
Liu HF, Ma J, Winter C, Bayer R. Recovery and purification process development for monoclonal antibody production. mAbs. 2010 Sep;2(5):480-99. DOI: 10.4161/mabs.2.5.12645
Tassinari E, Danielli L, Marchetti A, Rosellini M, Ricci C, Piazza P, et al. State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes. Hum Vaccin Immunother. 2024 Dec 19;21(1). DOI: 10.1080/21645515.2024.2440165
Galkin OY, Shirobokov VP, Grigorenko AA, Dugan OM, Lutsenko TM, Komar AG. Biotechnological foundations for the deve¬lopment of serological diagnostic tools for infectious and non-infectious diseases: monograph. Kyiv: NTUU "KPI"; 2015. 20 p.
Oliinyk OS, Palyvoda KO, Lugovskaya NE, Kolibo DV, Lugovskoy EV, Komisarenko SV. Recombinant single chain variable fragment antibodies (scFv) against Pro144-Leu155 fragment of human protein C. Ukr Biochem J. 2015;87(2):88-94.
Galkin OY, Besarab AB, Lutsenko TN. Characteristics of enzyme-linked immunosorbent assay for detection of IgG antibodies specific to Сhlamydia trachomatis heat shock protein (HSP-60). Ukr Biochem J. 2017;89(1):22-30. DOI: 10.15407/ubj89.01.022
Zhang Y, Cheng H, Yu P, Wang S, Dong H, Lu S, et al. High-throughput single-cell analysis reveals Omp38-specific monoclonal antibodies that protect against Acinetobacter baumannii infection. Emerg Microbes Infect. 2024 Dec 17;14(1). DOI: 10.1080/22221751.2024.2437243
Liu M, Ren T, Zhang L, Li P, Zhong Z, Zhou L, et al. Development of a monoclonal antibody specifically recognizing a linear epitope on the E1 protein of Getah virus. Virology. 2025 Jan;602:110315. DOI: 10.1016/j.virol.2024.110315
Xiao J, Yu S, Jiang K, He X, Bi L, Zhao P, et al. Identification of linear B cell epitopes on the leukotoxin protein of Fusobacterium necrophorum. Anaerobe. 2024 Dec;90:102884. DOI: 10.1016/j.anaerobe.2024.102884
Mitra S, Tomar PC. Hybridoma technology; advancements, clinical significance, and future aspects. J Genet Eng Biotechnol. 2021 Oct 18;19(1). DOI: 10.1186/s43141-021-00264-6
Galkin O, Dekhtyarenko N, Gorchakov V, Dugan O. Supervised medical biotechnology: Atlas of the discipline "Medical biotechnology" for students of the direction of training "Biotechnology". Kiyv: Politechnika; 2011. 36 p.
Fratz-Berilla EJ, Angart P, Graham RJ, Powers DN, Mohammad A, Kohnhorst C, et al. Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events. Biotechnol Bioeng. 2020 Jun 4;117(9):2802-15. DOI: 10.1002/bit.27436
Li F, Vijayasankaran N, Shen A, Kiss R, Amanullah A. Cell culture processes for monoclonal antibody production. mAbs. 2010 Sep;2(5):466-79. DOI: 10.4161/mabs.2.5.12720
Daya J, Cusick V, Mattila J. Characterization of ionic strength for X‐MuLV inactivation by low pH treatment for mono-clonal antibody purification. Biotechnol Bioeng. 2023 Apr 20;120(6):1605-13. DOI: 10.1002/bit.28379
Adjuvant use and monoclonal antibody production [Internet]. Institutional Animal Care and Use Committee. 2024 [cited 2025 Feb 8]. Available from: https://research.wayne.edu/iacuc/adjuvantuseandmonoclonalantibodyproduction
McCormick-Ell J, Connell N. Laboratory safety, biosecurity, and responsible animal use. ILAR J. 2019;60(1):24-33. DOI: 10.1093/ilar/ilz012
Barone PW, Wiebe ME, Leung JC, Hussein IT, Keumurian FJ, Bouressa J, et al. Viral contamination in biologic manufacture and implications for emerging therapies. Nat Biotechnol. 2020 Apr 27;38(5):563-72. DOI: 10.1038/s41587-020-0507-2
Pan X, de Souza MO, Figueiras FM, Huang A, Banach BB, Wolfe JR, et al. Optimized single-cell gates for yeast display screening. Protein Eng Des Sel. 2024 Dec 12; DOI: 10.1093/protein/gzae018
Sakaguchi A, Nakajima C, Sawano A, Tanaka Y, Kurihara Y. Rapid and reliable hybridoma screening method that is sui-table for production of functional structure-recognizing monoclonal antibody. J Biosci Bioeng. 2021 Jun;131(6):696-702. DOI: 10.1016/j.jbiosc.2021.02.006
Mortezagholi S, Maghsood F, Shojaeian S, Shokri F, Amiri MM, Ghorbani A, et al. Production and characterization of a panel of anti-mouse placenta-specific protein 1 (plac1) monoclonal antibodies. Anal Biochem. 2025 Jan;696:115682. DOI: 10.1016/j.ab.2024.115682
Arkhypova M, Deriabin O, Trokhymchuk T, Starosyla D, Atamaniuk V, Zavelevich M, et al. The influence of flavonoid compositions on Nrf2 transcription factor expression in case of infections triggered by influenza a virus and transmissible gastroenteritis coronavirus. Innov Biosyst Bioeng. 2023 Dec 15;7(4):48-56. DOI: 10.20535/ibb.2023.7.4.290103
Antibody hybridoma core - Fusion and screening [Internet]. Mayo Clinic. 2025 [cited 2025 Feb 8]. Available from: https://www.mayo.edu/research/core-resources/antibody-hybridoma-core/services/fusion-screening
Tomita M, Tsumoto K. Hybridoma technologies for antibody production. Immunotherapy. 2011 Mar;3(3):371-80. DOI: 10.2217/imt.11.4
Muhsin A, Rangel R, Vien L, Bover L. Monoclonal antibodies generation: Updates and protocols on hybridoma technology. Methods Mol Biol. 2022;2435:73-93. doi: 10.1007/978-1-0716-2014-4_6
Bols NC, Scharer JM, Phillips HA, Moo-Young M. Media for hybridoma growth and monoclonal antibody production. Biotechnol Adv. 1988 Jan;6(2):169-82. DOI: 10.1016/0734-9750(88)90003-1
O'Brien SA, Hu WS. Cell culture bioprocessing — the road taken and the path forward. Curr Opin Chem Eng. 2020 Dec;30:128-34. DOI: 10.1016/j.coche.2020.100663
Bergin A, Carvell J, Butler M. Applications of bio-capacitance to cell culture manufacturing. Biotechnol Adv. 2022 Oct;61:108048. DOI: 10.1016/j.biotechadv.2022.108048
Parks DR, Bryan VM, Oi VT, Herzenberg LA. Antigen-specific identification and cloning of hybridomas with a fluorescence-activated cell sorter. Proc National Acad Sci. 1979 Apr 1;76(4):1962-6. DOI: 10.1073/pnas.76.4.1962
Xu Y, Wang G, Xu M. Biohazard levels and biosafety protection for Mycobacterium tuberculosis strains with different virulence. Biosaf Health. 2020 Sep;2(3):135-41. DOI: 10.1016/j.bsheal.2020.04.001
Wang F, Liu LS, Li P, Lau CH, Leung HM, Chin YR, Tin C, et al. Cellular uptake, tissue penetration, biodistribution, and biosafety of threose nucleic acids: assessing in vitro and in vivo delivery. Mater Today Bio. 2022 May;100299. DOI: 10.1016/j.mtbio.2022.100299
Mizuno M, Matsuda J, Watanabe K, Shimizu N, Sekiya I. Effect of disinfectants and manual wiping for processing the cell product changeover in a biosafety cabinet. Regen Ther. 2023 Mar;22:169-75. DOI: 10.1016/j.reth.2023.01.009
Féraudet-Tarisse C, Vaisanen-Tunkelrott ML, Moreau K, Lamourette P, Créminon C, Volland H. Pathogen-free screening of bacteria-specific hybridomas for selecting high-quality monoclonal antibodies against pathogen bacteria as illustrated for Legionella pneumophila. J Immunol Methods. 2013 May;391(1-2):81-94. DOI: 10.1016/j.jim.2013.02.012
Soley A, Fontova A, Gálvez J, Sarró E, Lecina M, Bragós R, et al. Development of a simple disposable six minibioreactor system for suspension mammalian cell culture. Process Biochem. 2012 Apr;47(4):597-605. DOI: 10.1016/j.procbio.2011.12.022
Moraes JZ, Hamaguchi B, Braggion C, Speciale ER, Cesar FB, Soares GD, et al. Hybridoma technology: is it still useful? Curr Res Immunol. 2021;2:32-40. DOI: 10.1016/j.crimmu.2021.03.002
Doerner A, Rhiel L, Zielonka S, Kolmar H. Therapeutic antibody engineering by high efficiency cell screening. FEBS Lett. 2013 Nov 26;588(2):278-87. DOI: 10.1016/j.febslet.2013.11.025
Parray HA, Shukla S, Samal S, Shrivastava T, Ahmed S, Sharma C, et al. Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives. Int Immunopharmacol. 2020 Aug;85:106639. DOI: 10.1016/j.intimp.2020.106639
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 The Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The ownership of copyright remains with the Authors.
Authors may use their own material in other publications provided that the Journal is acknowledged as the original place of publication and National Technical University of Ukraine “Igor Sikorsky Kyiv Polytechnic Institute” as the Publisher.
Authors are reminded that it is their responsibility to comply with copyright laws. It is essential to ensure that no part of the text or illustrations have appeared or are due to appear in other publications, without prior permission from the copyright holder.
IBB articles are published under Creative Commons licence:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under CC BY 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
